Category Specific RSS

Next Science (ASX: NXS)

Next Science Ltd. engages in the research, development, and distribution of technologies with bacterial issue application. The company is headquartered in Chatswood, New South Wales. The firm’s principal activities include development and commercialization of XBIO technology. The XBIO technology is a non-toxic technology used in solving the problems of bacterial biofilms. The Company’s products include XPERIENCE, Blast X, SurgX and Bactisure. The XPERIENCE product is an antimicrobial solution used to prevent surgical site infections by rinsing away debris and microorganisms. SurgX Sterile Antimicrobial Gel is used to reduce surgical site and post-surgical infections by destroying planktonic and biofilm-based bacteria within the gel with sustained effectiveness for up to five days. The Blast X is an antimicrobial wound gel.

Here are the latest articles on Next Science (ASX: NXS)

Next Science sees wound care sales quadruple, boosts investment in direct sales

Sydney-based MedTech company Next Science (ASX: NXS) has reported a bumper result with its annual sales, reaching $33.7 million, a 90% increase compared to the previous year. This surge is primarily attributed to the expansion in the Wound Care and Surgical segments, driven by a strategic focus on direct sales and the successful implementation of

Next Science sees 54% reduction in inflammation after knee replacement surgery in study

Australia’s growing ageing population (older Aussies are expected to make up 23% of the population by 2026) is not free of health issues, ranging from obesity to cracking hips. This has benefitted some medical fields more than others. Over the past decade, there has been a 140% increase in knee replacement surgeries, shooting up to